Stocks and Investing
Stocks and Investing
Mon, February 29, 2016
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, February 26, 2016
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Kennen MacKay Maintained (BMRN) at Buy with Decreased Target to $125 on, Feb 26th, 2016
Kennen MacKay of RBC Capital, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $155 to $125 on, Feb 26th, 2016.
Kennen has made no other calls on BMRN in the last 4 months.
There is 1 other peer that has a rating on BMRN. Out of the 1 peers that are also analyzing BMRN, 0 agree with Kennen's Rating of Hold.
This is the rating of the analyst that currently disagrees with Kennen
- Joseph Schwartz of "Leerink Swann" Maintained at Buy with Decreased Target to $120 on, Tuesday, February 23rd, 2016